Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOAL II: Gemcitabine/Oxaliplatin/Rituximab plus Tafasitamab in relapsed/refractory aggressive B‑cell lymphoma
2024-514775-17-00Phase 2Completed
- Sponsor
- University Medical Center Mainz
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tafasitamab in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), aggressive B-cell lymphoma and 2 more (2 arms), sponsored by University Medical Center Mainz. Primary endpoint: Primary ORR within first 8 treatment cycles. Started Aug 2024; status: completed.
02
Drugs
tafasitamab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)aggressive B-cell lymphomafollicular lymphoma (FL)transformed B-cell lymphoma
Beyond the preview
Go deeper on 2024-514775-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514775-17-00.